



## **BioCryst to Present at JMP Securities Hematology & Oncology Summit**

December 5, 2022

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](https://www.biocryst.com) (Nasdaq: BCRX) today announced that the company will present virtually at the JMP Securities Hematology & Oncology Summit on Wednesday, December 7, 2022, at 11:40 a.m. ET.

Links to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst's website at <http://www.biocryst.com>.

### **About BioCryst Pharmaceuticals**

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including oral factor D inhibitors BCX9930 and BCX10013, which are in clinical development. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company's website at [www.biocryst.com](http://www.biocryst.com).

BCRXW

### **Investor Contact:**

John Bluth  
+1 919 859 7910  
[jbluth@biocryst.com](mailto:jbluth@biocryst.com)

### **Media Contact:**

Catherine Collier Kyroulis  
+1 917 886 5586  
[ckyroulis@biocryst.com](mailto:ckyroulis@biocryst.com)